Literature DB >> 12764870

Determination of the frequency of inadequate antibiotic therapy using calculation of indication failure (IF), cumulative indication failure (CIF), and balanced indication failure (BIF).

Heinz Burgmann1.   

Abstract

Because results of pathogen identification are often lacking when antibiotic therapy is initiated, treatment must frequently be instituted on an empirical basis. The type of empirical therapy will depend on the anticipated pathogen spectrum and naturally also on the prevailing resistance patterns. Inadequate antibiotic therapy may not only be associated with increased overall treatment costs, but will also have adverse effects on mortality. The clinician is frequently faced with an overabundant variety of microbiological data and may fail to interpret them correctly. Therefore, the present study has attempted to "translate" the available microbiological resistance data, frequently presented in the form of percentage rates, into concrete patient numbers and thus illustrate the frequency of inadequate antibiotic therapy. For this purpose, "Indication Failure" (IF), "Cumulative Indication Failure" (CIF) and "Balanced Indication Failure" (BIF) have been calculated based on available microbiological data. For the indication "nosocomial pneumonia", calculations of the BIF show that only one out of 67 or one out of 63 patients is inadequately treated with a therapy with cefepime or imipenem, while one out of 25 patients is inadequately treated when using ceftazidime. However, it must be pointed out that these calculations only represent an interpretation of microbiological data and the success of antibiotic therapy will ultimately also depend on parameters such as the pharmacodynamic properties of an antibiotic or on the immunocompetence of the patient treated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764870     DOI: 10.1046/j.1563-258x.2003.03018.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  6 in total

1.  Risk factors and outcome of nosocomial infections: results of a matched case-control study of ICU patients.

Authors:  E Girou; F Stephan; A Novara; M Safar; J Y Fagon
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

Review 2.  Nosocomial pneumonia in the critical care unit.

Authors:  H M Lode; T Schaberg; M Raffenberg; H Mauch
Journal:  Crit Care Clin       Date:  1998-01       Impact factor: 3.598

3.  Multicenter study of the in vitro activity of cefepime in comparison with five other broad-spectrum antibiotics against clinical isolates of Gram-positive and Gram-negative bacteria from hospitalized patients in Switzerland.

Authors:  Jürg Wüst; Reno Frei
Journal:  Clin Microbiol Infect       Date:  1999-05       Impact factor: 8.067

4.  In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.

Authors:  R Krause; H Mittermayer; G Feierl; F Allerberger; I Wendelin; A Hirschl; E C Reisinger
Journal:  Wien Klin Wochenschr       Date:  1999-07-30       Impact factor: 1.704

5.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.

Authors:  C M Luna; P Vujacich; M S Niederman; C Vay; C Gherardi; J Matera; E C Jolly
Journal:  Chest       Date:  1997-03       Impact factor: 9.410

6.  Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group.

Authors:  F Alvarez-Lerma
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.